518 related articles for article (PubMed ID: 19337958)
1. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Stovall DW; Pinkerton JV
Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
[TBL] [Abstract][Full Text] [Related]
2. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States.
Williams RE; Kalilani L; DiBenedetti DB; Zhou X; Granger AL; Fehnel SE; Levine KB; Jordan J; Clark RV
Climacteric; 2008 Feb; 11(1):32-43. PubMed ID: 18202963
[TBL] [Abstract][Full Text] [Related]
3. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study.
Garcia JT; Gonzaga F; Tan D; Ng TY; Oei PL; Chan CW
Menopause; 2010 Mar; 17(2):303-8. PubMed ID: 19934777
[TBL] [Abstract][Full Text] [Related]
4. MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms.
Leitman DC; Christians U
Expert Opin Investig Drugs; 2012 Jul; 21(7):1031-42. PubMed ID: 22616988
[TBL] [Abstract][Full Text] [Related]
5. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
6. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
Wang PH; Horng HC; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):127-34. PubMed ID: 17638620
[TBL] [Abstract][Full Text] [Related]
7. The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo.
Kwee SH; Tan HH; Marsman A; Wauters C
Maturitas; 2007 Sep; 58(1):83-90. PubMed ID: 17689896
[TBL] [Abstract][Full Text] [Related]
8. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
[TBL] [Abstract][Full Text] [Related]
10. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
11. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
12. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
14. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta and its selective ligands: an option for treatment of menopausal vasomotor symptoms?
Jarry H
Horm Mol Biol Clin Investig; 2013 Dec; 16(1):7-12. PubMed ID: 25436742
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Pinkerton JV; Stovall DW
Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
[TBL] [Abstract][Full Text] [Related]
17. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
Utian WH
Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
[TBL] [Abstract][Full Text] [Related]
18. Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.
McGregor C; Sau A; Ruddy SC; Leung D; Webb M; Durst T; Wright JS; Lagace D; Pratt MA
Endocrinology; 2014 Jul; 155(7):2480-91. PubMed ID: 24823389
[TBL] [Abstract][Full Text] [Related]
19. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial.
Grady D; Sawaya GF; Johnson KC; Koltun W; Hess R; Vittinghoff E; Kristof M; Tagliaferri M; Cohen I; Ensrud KE
Menopause; 2009; 16(3):458-65. PubMed ID: 19182698
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, multiple-dose escalation study of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) for moderate to severe menopausal symptoms and quality of life in postmenopausal women.
Wang CC; Cheng KF; Lo WM; Law C; Li L; Leung PC; Chung TK; Haines CJ
Menopause; 2013 Feb; 20(2):223-31. PubMed ID: 22990757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
